Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jef De Schutter"'
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
Patient characteristics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d730ee8d35666ac4f7fd891c80729e6d
https://doi.org/10.1158/1078-0432.22454784
https://doi.org/10.1158/1078-0432.22454784
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
(A) Median progression-free survival according to type of therapy in the KRAS and BRAF mutated KRAS 3'-UTR LCS6 SNP carriers, (B) Median progression-free survival according to type of therapy in the KRAS and BRAF mutated non-KRAS 3'-UTR LCS6 SNP carr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56dd150c6033ab1d6f7c9ec6ffe55646
https://doi.org/10.1158/1078-0432.22454787
https://doi.org/10.1158/1078-0432.22454787
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
Biologic characteristics of the patients according to the type of treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f0181c5f488bd5199ef417224ab146
https://doi.org/10.1158/1078-0432.22454793.v1
https://doi.org/10.1158/1078-0432.22454793.v1
Autor:
Sabine Tejpar, Eric Van Cutsem, Yves Humblet, Marc Peeters, Jean-Luc Van Laethem, Maria Debiec-Rychter, An Capoen, Wendy De Roock, Bart Biesmans, Jef De Schutter, Gert De Hertogh, Hubert Piessevaux, Steffen Fieuws, Nicola Personeni
Supplementary Tables S1-S4 from Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22edfb37b09a7e2f7904867ac454a78d
https://doi.org/10.1158/1078-0432.22439388
https://doi.org/10.1158/1078-0432.22439388
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
Purpose: An inherited mutation in KRAS (LCS6-variant or rs61764370) results in altered control of the KRAS oncogene. We studied this biomarker's correlation to anti-EGFR monoclonal antibody (mAb) therapy response in patients with metastatic colorecta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f17e5689d05866061396c32c374d8f7
https://doi.org/10.1158/1078-0432.c.6522834.v1
https://doi.org/10.1158/1078-0432.c.6522834.v1
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
Outcome and survival analysis according to KRAS 3'-UTR LCS6 genotypes and other clinical variables for the entire population.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2d08d5f36817b151d193f6e7b26c93
https://doi.org/10.1158/1078-0432.22454781
https://doi.org/10.1158/1078-0432.22454781
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
Predictive and prognostic factors by multivariate analyses (adjusted relative risks) for PFS and OS. A. Univariate analysis B. Multivariate analysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e49dac9749b1335e2d92b75a574a099
https://doi.org/10.1158/1078-0432.22454778.v1
https://doi.org/10.1158/1078-0432.22454778.v1
Autor:
Sabine Tejpar, Eric Van Cutsem, Yves Humblet, Marc Peeters, Jean-Luc Van Laethem, Maria Debiec-Rychter, An Capoen, Wendy De Roock, Bart Biesmans, Jef De Schutter, Gert De Hertogh, Hubert Piessevaux, Steffen Fieuws, Nicola Personeni
Purpose: To evaluate the usefulness and the pitfalls inherent to the assessment of the epidermal growth factor receptor (EGFR) gene copy number (GCN) by fluorescence in situ hybridization (FISH) for outcome prediction to cetuximab in metastatic color
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882b72fe4a8d56e4db87d6183935c3c2
https://doi.org/10.1158/1078-0432.c.6516861.v1
https://doi.org/10.1158/1078-0432.c.6516861.v1
Autor:
Sabine Tejpar, Hubert Piessevaux, Olivier Bouché, Camilla Pilati, Dongyun Yang, Wu Zhang, David W. Salzman, Wendy De Roock, Jef De Schutter, Bart Jacobs, Pierre Laurent-Puig, Heinz-Josef Lenz, Joanne B. Weidhaas, Zenia Saridaki
(A) Median progression free survival and (B) median overall survival, according to the KRAS 3'-UTR LCS6 SNP genotype status in patients treated with anti-EGFR moAbs monotherapy or in combination with chemotherapy as salvage treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9969766d0523d9ef3f7a0ae1c16233b5
https://doi.org/10.1158/1078-0432.22454790
https://doi.org/10.1158/1078-0432.22454790
Autor:
Philippe Rougier, George Fountzilas, Teresa Macarulla, Alice Gangloff, Sabine Tejpar, Bart Claes, Bruno Vincenzi, Vassiliki Kotoula, Giuseppe Tonini, Salvatore Siena, Frédéric Di Fiore, Mauro Delorenzi, Eric Van Cutsem, Alberto Bardelli, Federico Cappuzzo, Daniele Santini, Hubert Piessevaux, Sara De Dosso, Tine Plato Hansen, Konstantine T. Kalogeras, Milo Frattini, Miriam Martini, Diether Lambrechts, Josep Tabernero, Jef De Schutter, Francesca Molinari, Bart Biesmans, Camilla Qvortrup, Frédérique Penault-Llorca, Piercarlo Saletti, Fortunato Ciardiello, Andrea Sartore-Bianchi, David Bernasconi, Per Pfeiffer, Demetris Papamichael, Wendy De Roock, Pierre Laurent-Puig
Publikováno v:
De Roock, W, Claes, B, Bernasconi, D, De Schutter, J, Biesmans, B, Fountzilas, G, Kalogeras, K T, Kotoula, V, Papamichael, D, Laurent-Puig, P, Penault-Llorca, F, Rougier, P, Vincenzi, B, Santini, D, Tonini, G, Cappuzzo, F, Frattini, M, Molinari, F, Saletti, P, De Dosso, S, Martini, M, Bardelli, A, Siena, S, Sartore-Bianchi, A, Tabernero, J, Macarulla, T, Di Fiore, F, Gangloff, A O, Ciardiello, F, Pfeiffer, P, Qvortrup, C, Hansen, T P, Van Cutsem, E, Piessevaux, H, Lambrechts, D, Delorenzi, M & Tejpar, S 2010, ' Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis ', Lancet Oncology, vol. 11, no. 8, pp. 753-62 . https://doi.org/10.1016/S1470-2045(10)70130-3
Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving ce